Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer.

Bilen MA, Lowentritt B, Khilfeh I, Rossi C, Du S, Kinkead F, Diaz L, Pilon D, Ellis L, Shore ND

DOI: 10.1007/s12325-025-03207-6
Published: 2025 Jul
Container: Advances in therapy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s12325-025-03207-6,
  title = {Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer.},
  author = {Bilen MA and Lowentritt B and Khilfeh I and Rossi C and Du S and Kinkead F and Diaz L and Pilon D and Ellis L and Shore ND},
  year = {2025},
  journal = {Advances in therapy},
  doi = {10.1007/s12325-025-03207-6},
  url = {https://doi.org/10.1007/s12325-025-03207-6}
}

RIS

TY  - JOUR
TI  - Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer.
AU  - Bilen MA
AU  - Lowentritt B
AU  - Khilfeh I
AU  - Rossi C
AU  - Du S
AU  - Kinkead F
AU  - Diaz L
AU  - Pilon D
AU  - Ellis L
AU  - Shore ND
PY  - 2025
JO  - Advances in therapy
DO  - 10.1007/s12325-025-03207-6
UR  - https://doi.org/10.1007/s12325-025-03207-6
ER  -

APA

MA, B., B, L., I, K., C, R., S, D., F, K., L, D., D, P., L, E., & ND, S. (2025). Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer.. Advances in therapy. https://doi.org/10.1007/s12325-025-03207-6

Source records

pubmed · retrieved 2026-09-26T12:10:31.530Z